AlphaGenome 2 extends Google DeepMind's genomics model offering, but the source provides no performance evidence to establish broader significance.
Limits of the evidence: The performance and example findings are reported through DeepMind; the source says systematic tests across diseases and confirmation in new experiments are still needed.
What to watch
Assessment revised Nov 13, 2026
Google DeepMind Releases AlphaGenome 2 for Cell-Type-Specific Variant Effects
MarkTechPostNov 11, 2026First report
😺 DeepMind launched AlphaGenome 2 for DNA
The NeuronNov 12, 2026
Google’s AlphaGenome 2 predicts how DNA changes affect specific cells
The Rundown AINov 12, 2026
Update from The Rundown AI
First assessment, from MarkTechPost
No maturity ladder applies to this desk.
Sens.ai aggregates and assesses published reporting. The assessment above is machine generated; the original sources are authoritative.